We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FC icon
2251
Franklin Covey
FC
$228M
$237K ﹤0.01%
15,432
KERX
2252
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$237K ﹤0.01%
35,846
-54
-0.2% -$302
MXWL
2253
DELISTED
Maxwell Technologies Inc
MXWL
$235K ﹤0.01%
44,500
MACK
2254
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$235K ﹤0.01%
5,542
+1,500
+37% +$81.7K
LXU icon
2255
LSB Industries
LXU
$707M
$234K ﹤0.01%
25,173
-16,297
-39% -$162K
UTL icon
2256
Unitil
UTL
$995M
$232K ﹤0.01%
5,440
FFG
2257
DELISTED
FBL Financial Group
FFG
$232K ﹤0.01%
3,824
ISCA
2258
DELISTED
International Speedway Corp
ISCA
$232K ﹤0.01%
6,945
BOOM icon
2259
DMC Global
BOOM
$154M
$231K ﹤0.01%
21,500
HTLD icon
2260
Heartland Express
HTLD
$981M
$230K ﹤0.01%
13,243
-123,821
-90% -$2.21M
AVAV icon
2261
AeroVironment
AVAV
$9.61B
$229K ﹤0.01%
+8,250
New +$239K
SRCE icon
2262
1st Source
SRCE
$2.13B
$229K ﹤0.01%
7,056
IMGN
2263
DELISTED
Immunogen Inc
IMGN
$229K ﹤0.01%
74,200
+31,700
+75% +$199K
MMP
2264
DELISTED
Magellan Midstream Partners, L.P.
MMP
$229K ﹤0.01%
+3,010
New +$213K
ANF icon
2265
Abercrombie & Fitch
ANF
$4.89B
$228K ﹤0.01%
12,780
+4,800
+60% +$114K
CDE icon
2266
Coeur Mining
CDE
$18.9B
$228K ﹤0.01%
21,430
-24,100
-53% -$189K
CRAI icon
2267
CRA International
CRAI
$1.08B
$228K ﹤0.01%
+9,050
New +$204K
RPTP
2268
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$227K ﹤0.01%
42,300
IJH icon
2269
iShares Core S&P Mid-Cap ETF
IJH
$128B
$226K ﹤0.01%
7,580
MGNX icon
2270
MacroGenics
MGNX
$262M
$226K ﹤0.01%
+8,380
New +$189K
ECPG icon
2271
Encore Capital Group
ECPG
$2.13B
$225K ﹤0.01%
9,570
-5,600
-37% -$144K
MOD icon
2272
Modine Manufacturing
MOD
$10.8B
$225K ﹤0.01%
25,600
+9,000
+54% +$92.7K
SYNT
2273
DELISTED
Syntel Inc
SYNT
$225K ﹤0.01%
4,970
+100
+2% +$4.51K
MED icon
2274
Medifast
MED
$129M
$224K ﹤0.01%
+6,730
New +$217K
MWW
2275
DELISTED
Monster Worldwide Inc
MWW
$224K ﹤0.01%
93,900
+15,000
+19% +$43K

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.